Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Merck & Co., Inc. (NYSE:MRK) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, ...

Drug maker Merck announced Tuesday it will embark on an initiative to cut $3 billion in costs 2027, including an undisclosed ...

CEO Rob Davis referred to the cost reduction program as a 'reallocation' rather than a cut, with the savings to be reinvested ...

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition ...

The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...